Drug intelligence / Profile preview

GSK EZH2 compound 26

Development stage: Unknown
Lead developer: GSK

Overview

GSK EZH2 compound 26: sourced facts only. name: "Potent and orally bioavailable EZH2 inhibitors, such as 25 and 26, were discovered from 3 by optimizing substitutions at the piperidine ring." [PMID:40451463]; target: "Potent and orally bioavailable EZH2 inhibitors, such as 25 and 26, were discovered from 3 by optimizing substitutions at the piperidine ring." [PMID:40451463]; developer: "GSK, Research and Development, 1250 South Collegeville Road, Collegeville, PA 19426, United States." [PMID:40451463]

Targets

EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on GSK EZH2 compound 26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK EZH2 compound 26.